Dermatomyositis,Tofacitinib,anti-MDA5 antibody
Showing 1 - 25 of >10,000
Dermatomyositis, Adult Type Trial in Xi'an (JAK Inhibitor)
Recruiting
- Dermatomyositis, Adult Type
- JAK Inhibitor
-
Xi'an, Shaanxi, ChinaDepartment of Rheumatology, the First Affiliated Hospital of Xi'
Jul 15, 2021
Dermatomyositis, Adult Type, Interstitial Lung Disease Trial in Nanjing (triple therapy, dual-therapy)
Recruiting
- Dermatomyositis, Adult Type
- Interstitial Lung Disease
- triple therapy
- dual-therapy
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
May 20, 2022
ANCA Associated Vasculitis, Drug Use, JAK-STAT Pathway Deregulation Trial in Shanghai (Tofacitinib)
Completed
- ANCA Associated Vasculitis
- +2 more
-
Shanghai, Shanghai, ChinaDepartment of Rheumatology in Zhongshan hospital, Fudan Universi
Jul 20, 2021
Ulcerative Colitis, Thromboembolism Trial in Madrid (Tofacitinib, Infliximab Adalimumab y Golimumab)
Recruiting
- Ulcerative Colitis
- Thromboembolism
- Tofacitinib
- Infliximab Adalimumab y Golimumab
-
Madrid, SpainHospital Universitario de La Princesa
Aug 2, 2022
Idiopathic Inflammatory Myositis Trial (Daxdilimab, Placebo)
Not yet recruiting
- Idiopathic Inflammatory Myositis
- Daxdilimab
- Placebo
- (no location specified)
Dec 20, 2022
Dermatomyositis Trial in Washington (Abatacept)
Completed
- Dermatomyositis
-
Washington, District of Columbia2300 M Street, 9th floor. Medical Faculty Associates, The George
Apr 5, 2022
Psoriasis Trial in New York (Risankizumab-Rzaa, Punch biopsies of the skin at baseline visit, Punch biopsies of the skin at week
Recruiting
- Psoriasis
- Risankizumab-Rzaa
- +2 more
-
New York, New YorkThe Rockefeller Univesity
Jun 9, 2022
Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris Trial in United States (Moderna mRNA-1273,
Recruiting
- Rheumatoid Arthritis
- +8 more
- Moderna mRNA-1273
- +5 more
-
Los Angeles, California
- +24 more
Aug 17, 2022
Axial Spondyloarthritis Trial in Dhaka (Baricitinib 2mg, Tofacitinib 5 mg)
Recruiting
- Axial Spondyloarthritis
- Baricitinib 2mg
- Tofacitinib 5 mg
-
Dhaka, BangladeshBangabandhu Sheikh Mujib Medical University
Nov 1, 2023
Biologics or Small Molecule Therapies in Inflammatory Bowel
Completed
- Crohn's Disease
- Ulcerative Colitis
-
New York, New York
- +1 more
Jan 9, 2023
Lymphocyte Subsets of Peripheral Blood in Nonmyopathic
Recruiting
- Dermatomyositis
-
Jinan, Shandong, ChinaYanfeng Hou
Nov 19, 2023
Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome Trial in Orange (CAB-201 following preconditioning
Recruiting
- Idiopathic Inflammatory Myopathy
- +3 more
- CAB-201 following preconditioning with fludarabine and cyclophosphamide
-
Orange, CaliforniaUniversity of California Irvine
Nov 30, 2023
Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Richter's Transformation
- Glofitamab
- +4 more
-
Boston, Massachusetts
- +1 more
Sep 12, 2023
Rheumatoid Arthritis, Interstitial Lung Disease Trial in Mexico City (Tofacitinib)
Recruiting
- Rheumatoid Arthritis
- Interstitial Lung Disease
-
Mexico City, Tlalpan, MexicoInstituto Nacional de Enfermedades Respiratorias, Ismael Cosío V
Apr 4, 2022
NSCLC Trial in Beijing, Tianjin (TQB2450 injection, docetaxel injection matching , AL2846 capsules, TQB2450 matching , docetaxel
Recruiting
- Non-small Cell Lung Cancer
- TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules
- TQB2450 matching placebo, docetaxel injection, AL2846 matching placebo
-
Beijing, Beijing, China
- +2 more
Jun 19, 2023
Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis Trial (KYV-101, Cyclophosphamide,
Not yet recruiting
- Idiopathic Inflammatory Myopathies
- +3 more
- KYV-101
- +2 more
- (no location specified)
Nov 21, 2023
Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer Trial (ADU-1805, Pembrolizumab)
Not yet recruiting
- Solid Tumor, Adult
- +2 more
- (no location specified)
May 3, 2023
Rotavirus Infections, Diarrhea Trial (IRV on a 0- and 28-day schedule, IRV on a 0-, 28- and 56-day schedule, Placebo on Day 0,
Not yet recruiting
- Rotavirus Infections
- Diarrhea
- IRV on a 0- and 28-day schedule
- +3 more
- (no location specified)
Oct 8, 2023
Seasonal Allergic Rhinitis Trial in China (LP-003 dose 1, LP-003 dose 2, Placebo)
Recruiting
- Seasonal Allergic Rhinitis
- LP-003 dose 1
- +2 more
-
Beijing, Beijing, China
- +16 more
Sep 18, 2023
Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma Trial in Australia (AI-061)
Not yet recruiting
- Melanoma
- +16 more
-
Darlinghurst, New South Wales, Australia
- +3 more
May 12, 2023
